Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription

Rational therapeutic approach to frontotemporal dementia

Basar Cenik, Chantelle F. Sephton, Colleen M. Dewey, Xunde Xian, Shuguang Wei, Kimberley Yu, Wenze Niu, Giovanni Coppola, Sarah E. Coughlin, Suzee E. Lee, Daniel R. Dries, Sandra Almeida, Daniel H. Geschwind, Fen Biao Gao, Bruce L. Miller, Robert V. Farese, Bruce A. Posner, Gang Yu, Joachim Herz

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Progranulin (GRN) haploinsufficiency is a frequent cause of familial frontotemporal dementia, a currently untreatable progressive neurodegenerative disease. By chemical library screening, we identified suberoylanilide hydroxamic acid (SAHA), a Food and Drug Administration-approved histone deacetylase inhibitor, as an enhancer of GRN expression. SAHA dose-dependently increased GRN mRNA and protein levels in cultured cells and restored near-normal GRN expression in haploinsufficient cells from human subjects. Although elevation of secreted progranulin levels through a post-transcriptional mechanism has recently been reported, this is, to the best of our knowledge, the first report of a small molecule enhancer of progranulin transcription. SAHA has demonstrated therapeutic potential in other neurodegenerative diseases and thus holds promise as a first generation drug for the prevention and treatment of frontotemporal dementia.

Original languageEnglish (US)
Pages (from-to)16101-16108
Number of pages8
JournalJournal of Biological Chemistry
Volume286
Issue number18
DOIs
StatePublished - May 6 2011

Fingerprint

Frontotemporal Dementia
Transcription
Neurodegenerative diseases
Up-Regulation
Neurodegenerative Diseases
Small Molecule Libraries
Haploinsufficiency
Histone Deacetylase Inhibitors
United States Food and Drug Administration
Dementia
Cultured Cells
Screening
Therapeutics
Cells
Messenger RNA
Molecules
Pharmaceutical Preparations
vorinostat
Proteins

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription : Rational therapeutic approach to frontotemporal dementia. / Cenik, Basar; Sephton, Chantelle F.; Dewey, Colleen M.; Xian, Xunde; Wei, Shuguang; Yu, Kimberley; Niu, Wenze; Coppola, Giovanni; Coughlin, Sarah E.; Lee, Suzee E.; Dries, Daniel R.; Almeida, Sandra; Geschwind, Daniel H.; Gao, Fen Biao; Miller, Bruce L.; Farese, Robert V.; Posner, Bruce A.; Yu, Gang; Herz, Joachim.

In: Journal of Biological Chemistry, Vol. 286, No. 18, 06.05.2011, p. 16101-16108.

Research output: Contribution to journalArticle

Cenik, B, Sephton, CF, Dewey, CM, Xian, X, Wei, S, Yu, K, Niu, W, Coppola, G, Coughlin, SE, Lee, SE, Dries, DR, Almeida, S, Geschwind, DH, Gao, FB, Miller, BL, Farese, RV, Posner, BA, Yu, G & Herz, J 2011, 'Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: Rational therapeutic approach to frontotemporal dementia', Journal of Biological Chemistry, vol. 286, no. 18, pp. 16101-16108. https://doi.org/10.1074/jbc.M110.193433
Cenik, Basar ; Sephton, Chantelle F. ; Dewey, Colleen M. ; Xian, Xunde ; Wei, Shuguang ; Yu, Kimberley ; Niu, Wenze ; Coppola, Giovanni ; Coughlin, Sarah E. ; Lee, Suzee E. ; Dries, Daniel R. ; Almeida, Sandra ; Geschwind, Daniel H. ; Gao, Fen Biao ; Miller, Bruce L. ; Farese, Robert V. ; Posner, Bruce A. ; Yu, Gang ; Herz, Joachim. / Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription : Rational therapeutic approach to frontotemporal dementia. In: Journal of Biological Chemistry. 2011 ; Vol. 286, No. 18. pp. 16101-16108.
@article{db303953704e4cd68a86fce42595cd68,
title = "Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: Rational therapeutic approach to frontotemporal dementia",
abstract = "Progranulin (GRN) haploinsufficiency is a frequent cause of familial frontotemporal dementia, a currently untreatable progressive neurodegenerative disease. By chemical library screening, we identified suberoylanilide hydroxamic acid (SAHA), a Food and Drug Administration-approved histone deacetylase inhibitor, as an enhancer of GRN expression. SAHA dose-dependently increased GRN mRNA and protein levels in cultured cells and restored near-normal GRN expression in haploinsufficient cells from human subjects. Although elevation of secreted progranulin levels through a post-transcriptional mechanism has recently been reported, this is, to the best of our knowledge, the first report of a small molecule enhancer of progranulin transcription. SAHA has demonstrated therapeutic potential in other neurodegenerative diseases and thus holds promise as a first generation drug for the prevention and treatment of frontotemporal dementia.",
author = "Basar Cenik and Sephton, {Chantelle F.} and Dewey, {Colleen M.} and Xunde Xian and Shuguang Wei and Kimberley Yu and Wenze Niu and Giovanni Coppola and Coughlin, {Sarah E.} and Lee, {Suzee E.} and Dries, {Daniel R.} and Sandra Almeida and Geschwind, {Daniel H.} and Gao, {Fen Biao} and Miller, {Bruce L.} and Farese, {Robert V.} and Posner, {Bruce A.} and Gang Yu and Joachim Herz",
year = "2011",
month = "5",
day = "6",
doi = "10.1074/jbc.M110.193433",
language = "English (US)",
volume = "286",
pages = "16101--16108",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "18",

}

TY - JOUR

T1 - Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription

T2 - Rational therapeutic approach to frontotemporal dementia

AU - Cenik, Basar

AU - Sephton, Chantelle F.

AU - Dewey, Colleen M.

AU - Xian, Xunde

AU - Wei, Shuguang

AU - Yu, Kimberley

AU - Niu, Wenze

AU - Coppola, Giovanni

AU - Coughlin, Sarah E.

AU - Lee, Suzee E.

AU - Dries, Daniel R.

AU - Almeida, Sandra

AU - Geschwind, Daniel H.

AU - Gao, Fen Biao

AU - Miller, Bruce L.

AU - Farese, Robert V.

AU - Posner, Bruce A.

AU - Yu, Gang

AU - Herz, Joachim

PY - 2011/5/6

Y1 - 2011/5/6

N2 - Progranulin (GRN) haploinsufficiency is a frequent cause of familial frontotemporal dementia, a currently untreatable progressive neurodegenerative disease. By chemical library screening, we identified suberoylanilide hydroxamic acid (SAHA), a Food and Drug Administration-approved histone deacetylase inhibitor, as an enhancer of GRN expression. SAHA dose-dependently increased GRN mRNA and protein levels in cultured cells and restored near-normal GRN expression in haploinsufficient cells from human subjects. Although elevation of secreted progranulin levels through a post-transcriptional mechanism has recently been reported, this is, to the best of our knowledge, the first report of a small molecule enhancer of progranulin transcription. SAHA has demonstrated therapeutic potential in other neurodegenerative diseases and thus holds promise as a first generation drug for the prevention and treatment of frontotemporal dementia.

AB - Progranulin (GRN) haploinsufficiency is a frequent cause of familial frontotemporal dementia, a currently untreatable progressive neurodegenerative disease. By chemical library screening, we identified suberoylanilide hydroxamic acid (SAHA), a Food and Drug Administration-approved histone deacetylase inhibitor, as an enhancer of GRN expression. SAHA dose-dependently increased GRN mRNA and protein levels in cultured cells and restored near-normal GRN expression in haploinsufficient cells from human subjects. Although elevation of secreted progranulin levels through a post-transcriptional mechanism has recently been reported, this is, to the best of our knowledge, the first report of a small molecule enhancer of progranulin transcription. SAHA has demonstrated therapeutic potential in other neurodegenerative diseases and thus holds promise as a first generation drug for the prevention and treatment of frontotemporal dementia.

UR - http://www.scopus.com/inward/record.url?scp=79955534069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955534069&partnerID=8YFLogxK

U2 - 10.1074/jbc.M110.193433

DO - 10.1074/jbc.M110.193433

M3 - Article

VL - 286

SP - 16101

EP - 16108

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 18

ER -